Saturday 17 October 2026
Export DVA’s income statement to Excel — free account
DaVita Inc.
DVA Healthcare Medical Care Facilities
DaVita Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.6 billion, up 6.46% from fiscal 2024. In the quarter to June 2026, revenue grew 5.17%, EPS grew 56.5%, free cash flow grew 49.4% and total debt rose 4.40%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years.
187.31
1.85
−0.98%
Follow DVA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
13.37 | 11.23 | 13.97 | 17.83 |
P/S ratio |
0.72 | 0.62 | 0.75 | 1.03 | |
P/FCF ratio |
6.36 | 5.56 | 6.12 | 8.01 | |
P/Operating CF |
11.38 | 15.60 | 32.28 | 29.41 | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.43 | 1.33 | 1.47 | 1.75 | |
EV/EBITDA |
6.93 | 6.57 | 7.25 | 8.62 | |
EV/Operating CF |
10.06 | 9.61 | 10.02 | 11.15 | |
EV/FCF |
12.65 | 11.94 | 12.00 | 13.59 | |
Quick Ratio |
1.26 | 1.19 | 1.31 | 1.36 | |
Current Ratio |
1.36 | 1.29 | 1.42 | 1.47 | |
Net Debt/EBITDA |
13.87 | 12.96 | 15.10 | 13.45 | |
Debt/Assets |
58.68% | 59.91% | 61.22% | 61.08% | |
Debt/Equity |
(33.86) | (28.02) | (22.49) | (22.44) | |
Asset Turnover |
0.76 | 0.78 | 0.80 | 0.80 | |
Operating CF/Net income |
5.60 | 2.31 | 1.62 | 1.85 | |
Capex/Depreciation |
(0.88) | (0.77) | (0.55) | (1.01) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
12.12% | 13.05% | 12.35% | 11.91% | |
Intangible Assets out of Total Assets |
0.44 | 0.44 | 0.45 | 0.44 | |
Share Based Compensation of Revenue |
1.14% | 1.06% | 0.82% | 0.73% | |
Graham Net Nets |
(1.44) | (1.64) | (1.34) | (0.97) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
7.48% | 8.91% | 7.16% | 5.61% | |
Free Cash Flow Yield |
15.72% | 18.00% | 16.35% | 12.48% | |
Revenue per Share |
47.45 | 48.77 | 50.68 | 54.86 | |
Operating CF per Share |
11.68 | 7.28 | 4.76 | 7.57 | |
Capex per Share |
(2.17) | (1.93) | (1.46) | (2.61) | |
Free Cash Flow per Share |
9.51 | 5.35 | 3.30 | 4.95 | |
Cash per Share |
11.46 | 10.54 | 11.11 | 11.91 | |
Shareholders Equity per Share |
(4.22) | (5.03) | (7.07) | (7.44) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(4.22) | (5.03) | (7.07) | (7.44) | |
Free Cash Flow |
685.38 | 397.13 | 222.53 | 320.92 | |
Working Capital |
1,094.70 | 916.37 | 1,195.22 | 1,334.21 | |
Capital Expenditures |
(156.15) | (143.59) | (98.30) | (169.15) | |
Net Current Asset Value |
(13,748.29) | (13,795.83) | (13,913.02) | (14,001.83) | |
EV/EBIT |
9.30 | 8.87 | 9.74 | 11.50 | |
Capex to Sales |
0.05 | 0.04 | 0.03 | 0.05 | |
Price to Operating Income |
4.68 | 4.13 | 4.96 | 6.77 | |
| Other line items | |||||
Average Receivables |
2,808.60 | 2,758.36 | 2,885.38 | 3,060.22 | |
Average Payables |
571.92 | 621.67 | 643.70 | 655.14 | |
Average Inventory |
134.05 | 147.59 | 146.07 | 148.92 | |
Average Assets |
17,529.82 | 17,382.69 | 17,309.20 | 17,601.23 | |
Average Common Equity |
141.22 | 11.07 | (241.45) | (294.97) |
Columns are period end dates